PATENT LICENSE AGREEMENTPatent License Agreement • January 23rd, 2009 • Panacos Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
WHEREAS, pursuant to an Asset Purchase Agreement dated as of January 20, 2009, by and between Panacos and Myriad (“Purchase Agreement”), Myriad acquired certain assets from Panacos used or which Myriad intends to use in connection with the development (preclinical and clinical), manufacture and commercialization of 3-O-(3’,3’-dimethylsuccinyl) betulinic acid and salts and solvates thereof, and polymorphs thereof (“Bevirimat”);
UNC/NIIGATA/PANACOS LICENSE AGREEMENTLicense Agreement • January 23rd, 2009 • Panacos Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • North Carolina
UNC/NIIGATA/PANACOS LICENSE AGREEMENT (this “Agreement”), effective as of January 20, 2009 (the “Effective Date”), between THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL having an address at CB #4105, 308 Bynum Hall, Chapel Hill, NC (hereinafter referred to as “University”), NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES having an address at 5-13-2 Kamishin’Ei-cho Niigata 950-2081, Japan (“Niigata”) and PANACOS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware and having an address at 209 Perry Parkway, Gaithersburg, MD 20877 (together with its Affiliates hereinafter referred to as “Licensee”).
ASSET PURCHASE AGREEMENT by and between PANACOS PHARMACEUTICALS, INC. as Seller, and MYRIAD PHARMACEUTICALS, INC. as Buyer Dated as of January 20, 2009Asset Purchase Agreement • January 23rd, 2009 • Panacos Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS ASSET PURCHASE AGREEMENT (as may be amended, modified, or supplemented from time to time as provided herein, this “Agreement”) is made as of the 20th day of January, 2009, by and between PANACOS PHARMACEUTICALS, INC., a Delaware corporation (“Seller”), and MYRIAD PHARMACEUTICALS, INC., a Delaware corporation (“Buyer”). Seller and Buyer are referred to collectively herein as the “Parties” and each, individually as a “Party.”
